Bisphosphonates are mainly used for the inhibition of osteoclast-mediated bone resorption but have also been shown to induce γδ T cell activation. Using IL-2 primed cultures of CD56 + peripheral blood mononuclear cells, we show here that zoledronic acid (zoledronate) could induce IFN-γ production not only in γδ T lymphocytes but, surprisingly, also in NK cells in a fashion that depended on antigen-presenting cells, which share properties of inflammatory monocytes and dendritic cells (DC-like cells).
A B S T R A C T
Bisphosphonates are mainly used for the inhibition of osteoclast-mediated bone resorption but have also been shown to induce γδ T cell activation. Using IL-2 primed cultures of CD56 + peripheral blood mononuclear cells, we show here that zoledronic acid (zoledronate) could induce IFN-γ production not only in γδ T lymphocytes but, surprisingly, also in NK cells in a fashion that depended on antigen-presenting cells, which share properties of inflammatory monocytes and dendritic cells (DC-like cells).
In the presence of γδ T lymphocytes, DC-like cells were rapidly eliminated and NK cell IFN-γ production was silenced. Conversely, in the absence of γδ T lymphocytes, DC-like cells were spared allowing NK cell IFN-γ production to proceed. γδ T cellindependent NK cell activation in response to zoledronate was due to downstream depletion of endogenous prenyl pyrophosphates and subsequent caspase-1 activation in DC-like cells, which then provide mature IL-18 and IL-1ß for the activation of IL-2 primed NK cells. Pharmacologic inhibition of caspase-1 almost completely abolished IFN-γ production in both, NK cells and γδ T lymphocytes, indicating that caspase-1 mediated cytokine maturation is the crucial mechanism underlying innate lymphocyte activation in response to zoledronate.
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INTRODUCTION
The bisphosphonates, zoledronate and pamidronate, are approved by the FDA for the treatment of metastatic bone disease of hematopoietic tumors such as multiple myeloma 1, 2 and nonhematopoietic tumors such as breast 3 and prostate cancer. 4 Inhibition of farnesyl pyrophosphate synthase, an enzyme of the mevalonate pathway for cholesterol biosynthesis and protein prenylation, 5 is one important mechanism for bisphosphonate effects on bone resorption. 1, 4 Inhibition of farnesyl pyrophosphate synthase leads to farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) deprivation and the subsequent failure to perform farnesylation and geranylgeranylation of small guanosine triphosphatases (GTPases) of the RAS superfamily. Inhibition of RAS signalling due to the disruption of membrane anchoring of these GTPases eventually prevents osteoclast-mediated bone resorption. 6, 7 In addition to their effects on bone metabolism, bisphosphonates may have immunomodulatory effects, particularly on the innate immune system. [8] [9] [10] [11] Evidence for the stimulation of γδ T lymphocytes by bisphosphonates was obtained, when expansion of γδ T lymphocytes was observed in patients, who had acute-phase reactions after their first treatment with pamidronate. 12 Inhibition of FPP synthase by bisphosphonates leads to the accumulation of isopentenyl pyrophosphate (IPP), that can be specifically recognized by γδ T lymphocytes expressing the Vδ2Vγ9 T cell receptors. 13 Hematopoietic tumor cell lines such as Daudi (Burkitt lymphoma) or RPMI 8226 (myeloma) are specifically recognized and lysed by these γδ T lymphocytes in vitro. 14, 15 Moreover, γδ T lymphocytes have recently been shown to recognize and kill zoledronate-sensitized chronic myelogenous leukemia cells even after acquisition of imatinib resistance. 16 Accumulation of mevalonate metabolites in 
MATERIAL AND METHODS

Reagents and antibodies
Zoledronate (Zometa®) was from Novartis Pharma (Nürnberg, Germany).
Pamidronate (Pamidronat Dinatrium Mayne) was obtained from Mayne Pharma (Munich, Germany). FPP and GGPP were purchased from Echelon Biosciences (Salt Lake City, UT). Stock solutions of FPP and GGPP were prepared in H 2 0. Stock solutions were pre-diluted in culture medium. The maximal amount of H 2 0 was calculated to be 0.2 µl per 200 µl (96 well). In control experiments, this had no effect.
Recombinant human IL-2 (Proleukin®) was from Novartis. Caspase-1 inhibitor AcTyr-Val-Ala-Asp-2,6-dimethylbenzoyloxymethyl-ketone (YVAD) was purchased from Alexis Biochemicals (San Diego, California). was from MBL (Nagoya, Japan); neutralizing anti-IL-1ß (8516) and anti-IL-12 (24910) were from R&D. IgG1 control antibody (103.7) was from BD Biosciences. 
Cytokine measurements
Cytokine levels were assessed on day 1-3 in culture supernatants using cytometric Cytokine Bead Arrays (CBA, BD Biosciences). The Th1/Th2 cytokine bead array 
Statistical analyses
Individual group comparisons were performed using independent student t tests and Excel as well as SPSS 13.0 software. Differences for which P was < .05 were reported as significant.
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RESULTS
Zoledronate is more potent than pamidronate in inducing IFN-γ production in
CD56
+ PBMCs: role of CD56 + inflammatory DC-like cells
In extension of our previous studies of DC-mediated γδ T cell activation, 24 we compared the immunostimulatory capacities of zoledronate and pamidronate ( Figure   1A ), which both inhibit FPP synthase within the mevalonate pathway ( Figure 1B) . In previous studies, CD56 + PBMCs proved to be a suitable and reliable experimental system for the study of DC-mediated innate lymphocyte activation. Figure 1 ). We and others have previously characterized these circulating DC-like cells [24] [25] [26] [27] and found that they are phenotypically similar to monocyte-derived DCs generated in vitro with GM-CSF and type 1 IFN. 28, 29 Such IFN-induced DCs, which express elevated levels of molecules related to antigen presentation and potently induce antigen-specific immune responses in vitro and in vivo, 28, 30, 31 were recently shown to be CD56 + CD14 + . 29 We have recently found that circulating CD56 + DC-like cells appear to be the preferred accessory cells for NK cell activation in response to stimulation with The potency of bisphosphonates is assessed by their relative ability to inhibit osteoclast function. A ranking of anti-osteoclast activity indicates that zoledronate, which differs from pamidronate by having a heterocyclic side chain containing two nitrogens ( Figure 1A ), is much more potent than pamidronate. 1 Consistently, zoledronate induced significantly higher amounts of IFN-γ ( Figure 3A , left panel; P < .01).
Magnetic depletion of CD14 + DC-like cells from CD56 + PBMCs prior to stimulation abolished IFN-γ production almost completely ( Figure 3A , right panel; P < .05)
confirming that bisphosphonate-induced IFN-γ production requires accessory cells. 13, 24 In contrast, however, we surprisingly observed that IFN-γ production in response to zoledronate, which occurred in a time-and dose-dependent fashion or for CD14 to identify DC-like cells.
As a first step, we monitored DC-like cells. After stimulation with IL-2 alone, DC-like cells could be detected. In the presence of IL-2 plus zoledronate, however, DC-like cells were rapidly eliminated indicative of either γδ T cell cytotoxicity directed against DC-like cells or NK cell cytotoxicity costimulated by zoledronate-activated γδ T lymphocytes. 23 In contrast, in the absence of γδ T lymphocytes, which were depleted prior to cell stimulation, DC-like cells survived even in the presence of zoledronate indicating that γδ T lymphocytes control the survival of DC-like cells. Figure 4A also shows that, after T cell depletion, there was residual IFN-γ production, which cannot be attributed to γδ T lymphocytes.
In replete CD56 + PBMCs, zoledronate was more potent in inducing IFN-γ production in TCRVδ2 + γδ T lymphocytes ( Figure 4B , upper panel) (P < .05).
However, a substantial TCRVδ2-negative population also produced IFN-γ in response to zoledronate ( Figure 4B ). This IFN-γ producing population also lacked CD3 ( Figure 4B , lower panel) and could thus be identified as NK cells (CD56
To further characterize and identify CD56 + CD3 -cells as NK cells, we performed staining of NKp46 (CD335), which is a member of the natural cytotoxicity receptor (NCR) family and considered to be a universal human NK cell marker. 33 We found that CD3 -cells were positive for NKp46 (supplemental Figure 2) irrevocably demonstrating that they were NK cells.
As an alternative to separation with microbeads, fluorescence-activated cell sorting (FACS) of PBMCs was also performed. Supplemental Figure 3A demonstrates that co-cultures of NK cells and CD56 + DC-like cells prepared by FACS mount similar synergistic IFN-γ responses to zoledronate plus IL-2. In addition, synergistic upregulation of IL-1ß production is shown (supplemental Figure 3B ).
To test whether zoledronate-induced IFN-γ production in NK cells depends on γδ T lymphocytes, which have recently been shown to costimulate NK cell cytotoxicity, induced strong IFN-γ production in both, γδ T lymphocytes and NK cells already on day 1, whereas IFN-γ production appeared to decline in γδ T lymphocytes on day 2
and was again silenced in NK cells ( Figure 5 ). In the absence of T lymphocytes including γδ T lymphocytes, DC-like cells (arrows) survived and NK cell IFN-γ Depletion of prenyl pyrophosphates such as GGPP can lead to the activation of caspase-1. 34, 35 Caspase-1 cleaves the proforms of IL-18 and IL-1ß to generate the mature, bioactive cytokines, 36, 37 which are both well known for their ability to enhance IFN-γ production. 33, 38, 39 We found that antibodies neutralizing IL-18 bioactivity Since both cytokines, IL-18 and IL-1ß, require caspase-1 for activation, 40 we also tested the effects of the caspase-1 inhibitor YVAD. 41 YVAD alone was capable of abrogating zoledronate-induced intracellular IFN-γ production not only in NK cells but also in γδ T lymphocytes ( Figure 7A ) (P < .01), whereas the DMSO solvent control had no effect. As a consequence, the total level of IFN-γ in culture supernatants was reduced by more than 90 % ( Figure 7B γδ T cell-independent NK cell activation depended on DC-like cell-derived IL-18
and IL-1ß, since neutralization of these two cytokines almost completely abolished NK cell IFN-γ production ( Figure 6 ). Both, IL-18 and IL-1ß are produced as proforms by myeloid cells. 38 Active caspase-1 is required in these cells to enzymatically cleave the proforms for the subsequent release of bioactive, mature IL-18 and IL-1ß. 40 Accordingly, we found that the specific caspase-1 inhibitor YVAD 41 strongly inhibited zoledronate-induced IFN-γ production in NK cells ( Figure 7A ). The potential of IL-18
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From and IL-1ß to synergize with IL-2 for the induction of IFN-γ in NK cells is well established. 33, 38, 42, 43 Downstream depletion of endogenous prenyl pyrophosphates was responsible for the zoledronate-induced NK cell response, since we observed that addition of FPP strongly and GGPP almost completely inhibited NK cell IFN-γ production ( Figure 6 ). It has previously been demonstrated that depletion of the isoprenoid pyrophosphates FPP and GGPP ( Figure 1B) can result in the activation of caspase-1. 34 In the absence of appropriate activation signals, isoprenoids prevented the activation of caspase-1 by suppressing autoprocessing of caspase-1. Conversely, when isoprenoid formation was inhibited, the suppression of caspase-1 autoprocessing was abrogated resulting in caspase-1 activation. 34 Likewise, in our work zoledronatemediated inhibition of isoprenoid formation resulted in caspase-1 activation and in the release of mature, active IL-18 and IL-1ß ( Figure 6 and 7) . The emerging mechanism of zoledronate-induced activation and regulation of IL-2 primed NK cells is summarized in supplemental Figure 6 .
Our current observations are corroborated by our recent finding that statins can also induce NK cell activation. 25 Statins, which are primarily used to control hypercholesterolemia, have also been proposed as anticancer agents. 44 In contrast to bisphosphonates, which inhibit FPP synthase, statins inhibit hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase, the first committed step of the mevalonate pathway ( Figure 1B) . Collectively, our observations indicate that inhibition of the mevalonate pathway for protein prenylation either mediated by the bisphosphonate zoledronate (this study) or by statins such as simvastatin 25 is also a potent signal for NK cell activation. It may therefore be of interest to examine the role of NK cells in bisphosphonate-and statin-based cancer therapy and chemoprevention.
For
The translation of isoprenoid pyrophosphate deprivation into caspase-1 mediated inflammation, which we observed here during zoledronate-induced inhibition of mevalonate metabolism, has recently also been observed in mevalonate kinase deficiency (MKD), a rare hereditary auto-inflammatory syndrome. 45 In MKD the enzyme is inactive due to mutations of the encoding gene. Lack of mevalonate kinase, the second enzyme of the mevalonate pathway ( Figure 1B) , results in GGPP deprivation followed by Nalp3-dependent caspase-1 activation and maturation of bioactive IL-1ß. The inflammatory phenotype of MKD, which includes periodic fevers, is consistent with many of the well known biological effects of IL-1ß. 46 Together with our previous work, 24, 25 
27
A severe toxic effect of intravenous bisphosphonates is osteonecrosis of the jaw. 47 The risk of development of osteonecrosis of the jaw is dependent on cumulative dose and potency of the agent. The risk is clearly increased for zoledronate, which is approximately 1000-fold more potent than pamidronate. 1 It will be important to clarify whether zoledronate-mediated NK cell activation, as reported here, can contribute to the development of osteonecrosis of the jaw, which can be considered an IFN-γ levels were determined in culture supernatants. One out of three independent experiments is shown.
